Literature DB >> 23892474

Evaluation of initial heparin infusion rates for a high-dose protocol.

Adam Smith1, Eileen M Stock, Nathan Fewel, Michael Rose, Carrie L Griffiths.   

Abstract

Unfractionated heparin is widely used as anticoagulant therapy for thrombotic disease. However, determining appropriate dosing by intravenous infusion is highly variable in practice. Multiple standardized protocols have been adopted, including a weight-based nomogram entailing a loading dose of 80 U/kg, followed by an initial infusion rate of 18 U/kg/h. In some instances, 18 U/kg/h has resulted in supratherapeutic activated partial thromboplastin time (aPTT). This study aimed to determine if an initial heparin infusion rate of 14 U/kg/h per a high-dose protocol achieved therapeutic anticoagulation more rapidly than 18 U/kg/h. A retrospective chart review performed at a Veterans Health Administration facility located in the southwestern U.S. identified 129 patients hospitalized from January 2009 to August 2011 receiving a high-dose protocol for heparin with an initial infusion rate of 14 or 18 U/kg/h. The proportion of patients achieving subtherapeutic, at goal, or supratherapeutic aPTT on two subsequent mornings was determined. Time to reach therapeutic aPTT was assessed with a multivariable generalized linear model. Patients provided 18 U/kg/h for heparin anticoagulation therapy experienced elevated aPTT values initially. Also, these patients generally took 1.41 times longer to reach therapeutic aPTT than patients receiving 14 U/kg/h [estimate = 0.34, 95% CI 0.11, 0.57; p < 0.01]. Larger body mass index led to increased time to reach therapeutic anticoagulation. This study's results suggest that patients may benefit from receiving an initial heparin infusion rate of 14 U/kg/h over 18 U/kg/h. Decreasing the time to therapeutic aPTT may further help reduce workload from monitoring and dose titrations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23892474     DOI: 10.1007/s11239-013-0963-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  32 in total

Review 1.  Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.

Authors:  J Hirsh; S S Anand; J L Halperin; V Fuster
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

2.  Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin.

Authors:  Siddharth Verma; Shumei Kato; Ronald Blum; Ilan Shapira; Patricia Friedmann; Mala Varma
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

Review 3.  Venous thromboembolism.

Authors:  Andrew D Blann; Gregory Y H Lip
Journal:  BMJ       Date:  2006-01-28

Review 4.  Haemostatic problems in liver disease.

Authors:  D A Kelly; E G Tuddenham
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

5.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

6.  Hemostatic changes in patients with liver cirrhosis.

Authors:  C H Ho; M C Hou; H C Lin; F Y Lee; J C Wu; S D Lee
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  1999-06

7.  Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity.

Authors:  Jeffrey F Barletta; Jaculin L DeYoung; Karen McAllen; Randal Baker; Kevin Pendleton
Journal:  Surg Obes Relat Dis       Date:  2008-06-30       Impact factor: 4.734

Review 8.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  Optimal therapeutic level of heparin therapy in patients with venous thrombosis.

Authors:  R D Hull; G E Raskob; D Rosenbloom; J Lemaire; G F Pineo; B Baylis; J S Ginsberg; A A Panju; P Brill-Edwards; R Brant
Journal:  Arch Intern Med       Date:  1992-08

10.  Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding.

Authors:  H A Holm; U Abildgaard; S Kalvenes
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.